HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ALEBUND-B

31.480

+0.2200.70%

Volume:233.50K

Turnover:7.32M

Market Cap:10.96B

PE:-10.25

High:32.000

Open:30.640

Low:30.440

Close:31.260

52wk High:46.820

52wk Low:22.720

Shares:348.00M

HK Float Shares:236.00M

Volume Ratio:0.54

T/O Rate:0.10%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-3.071

ROE:--

ROA:-33.01%

PB:6.67

PE(LYR):-10.25

PS:76.58

Loading ...

Overview Company News Filings

Unpacking ALEBUND-B's First Half Results: The Compounding Growth Logic of a Kidney Disease-Focused Biopharma

Alebund Pharmaceuticals HY26 Net Loss Narrows 22.5% to RMB 162.55 Million; Revenue Rises to RMB 104.16 Million

Alebund Pharmaceuticals (Jiangsu) Ltd - Board Did not Recommend Distribution of an Interim Dividend

THOMSON REUTERS

Alebund Pharmaceuticals (Jiangsu) Ltd - Hy Loss Attributable Rmb162.6 Mln

THOMSON REUTERS

Hong Kong Stock Alert | ALEBUND-B (09637) Surges Over 6% on Dual Catalysts of Index Inclusion and Earnings, with Mircera Commercialization Poised for Growth

Earning Preview: ALEBUND-B Q2 revenue expected to increase, institutions cautious on margin recovery

Alebund Pharmaceuticals Held Extraordinary General Meeting; Auditor Appointment Approved

Alebund Pharmaceuticals Sets 26 August 2026 Board Meeting to Approve 1H26 Interim Results

Bulletin Express

Alebund Pharmaceuticals Schedules Board Meeting to Review Interim Results

Alebund Pharma's Application for Hyperphosphatemia Drug Accepted in China

MT Newswires Live

Alebund Pharma’s AP301 Capsule NDA Accepted by China’s NMPA for Dialysis-Related Hyperphosphatemia

Bulletin Express

Alebund Pharma Says China NMPA Accepts AP301 Hyperphosphatemia NDA for Review

Alebund Pharmaceuticals (Jiangsu) - Nmpa China Accepts Nda for AP301 Capsules for Hyperphosphatemia in Ckd Dialysis Patients

THOMSON REUTERS

Alebund Pharma Expects H1 Revenue RMB 103 Million-RMB 106 Million, up About 750%-775%

Alebund Pharmaceuticals Completes 8.51 Million-Share Over-Allotment, Total Issued Capital Rises to 348.37 Million

Bulletin Express

Hong Kong Stock Moves: ALEBUND-B Rises Over 6% After Global Phase IIb Trial Milestone for AP306

Alebund Pharmaceuticals Publishes July 2026 Articles of Association, Confirms RMB348.37 Million Capital and Governance Framework

Bulletin Express

Alebund Pharmaceuticals Amends Bylaws to Update Registered Capital to RMB 348.37 Million

ALEBUND-B (09637) Issued 8.51 Million Shares Following Full Exercise of Over-Allotment Option

Alebund Pharma Nets HK$185 Million From Full Exercise of IPO Over-Allotment Option

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/09637/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09637\",,,,,undefined,":{"symbol":"09637","market":"HK","secType":"STK","nameCN":"ALEBUND-B","latestPrice":31.48,"timestamp":1788163726708,"preClose":31.26,"halted":0,"volume":233502,"delay":0,"changeRate":0.00703774792066535,"floatShares":236000000,"shares":348000000,"eps":-3.071284,"marketStatus":"Not Yet Opened","change":0.22,"latestTime":"08-31 16:08:46","open":30.64,"high":32,"low":30.44,"amount":7323436,"amplitude":0.049904,"askPrice":31.54,"askSize":200,"bidPrice":31.48,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-2.326,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":0,"adr":0,"listingDate":1782662400000,"exchange":"SEHK","adjPreClose":31.26,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":0.5386694449451177,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09637\",,,,,undefined,":{"symbol":"09637","floatShares":236000000,"roa":"-33.01%","roe":"--","lyrEps":-3.071284,"volumeRatio":0.5386694449451177,"shares":348000000,"dividePrice":0,"high":32,"amplitude":0.049904,"preClose":31.26,"low":30.44,"week52Low":22.72,"pbRate":"6.67","psRate":"76.58","week52High":46.82,"institutionHeld":0,"latestPrice":31.48,"committee":-0.333333,"eps":-3.071284,"divideRate":0,"volume":233502,"delay":0,"ttmEps":-2.326,"open":30.64,"prevYearClose":22.6,"prevWeekClose":31.26,"prevMonthClose":31.48,"prevQuarterClose":45.92,"fiveDayClose":32.46,"twentyDayClose":29.48,"sixtyDayClose":22.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09637\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"09637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09637\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":3,"updateTime":1788019200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09637","date":"2026-08-28","current":-13.533964,"percent":0.465116,"low":-18.066068,"twenty":-13.077865,"median":-11.990608,"eighty":-10.959851,"high":-8.87585,"avg":-12.238532,"sd":1.702985,"marketCap":10623780741},"quantilePoints":[{"date":"2026-06-26","current":-8.87585,"twenty":-8.87585,"median":-8.87585,"eighty":-8.87585,"marketCap":7680660420},{"date":"2026-07-03","current":-11.883178,"twenty":-18.03155,"median":-11.883178,"eighty":-9.78101,"marketCap":10290725554},{"date":"2026-07-10","current":-12.164969,"twenty":-13.966639,"median":-11.847257,"eighty":-11.12129,"marketCap":10521825071},{"date":"2026-07-17","current":-10.947234,"twenty":-12.322489,"median":-11.455859,"eighty":-10.783874,"marketCap":9502268378},{"date":"2026-07-24","current":-11.320561,"twenty":-11.939536,"median":-11.377389,"eighty":-10.939493,"marketCap":9828526520},{"date":"2026-07-31","current":-10.642718,"twenty":-11.840073,"median":-11.194259,"eighty":-10.78337,"marketCap":9257574772},{"date":"2026-08-07","current":-12.743391,"twenty":-12.396338,"median":-11.399787,"eighty":-10.889159,"marketCap":11106370909},{"date":"2026-08-14","current":-13.03884,"twenty":-12.987078,"median":-11.462395,"eighty":-10.903987,"marketCap":11378252693},{"date":"2026-08-21","current":-12.870195,"twenty":-13.077865,"median":-11.725167,"eighty":-10.931752,"marketCap":11255905890},{"date":"2026-08-28","current":-12.144658,"twenty":-13.077865,"median":-11.990608,"eighty":-10.959851,"marketCap":10623780741}],"updateTime":1788214190767},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09637\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1135812657","title":"Unpacking ALEBUND-B's First Half Results: The Compounding Growth Logic of a Kidney Disease-Focused Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=1135812657","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135812657?lang=en_us&edition=fundamental","pubTime":"2026-08-27 08:04","pubTimestamp":1787789077,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) delivered its inaugural interim results on August 26, marking a significant milestone since its listing, with revenue scaling to 8.6 times the figure reported in the same period...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1191","159938","09637","BK1515","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662797855","title":"Alebund Pharmaceuticals HY26 Net Loss Narrows 22.5% to RMB 162.55 Million; Revenue Rises to RMB 104.16 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797855","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662797855?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:04","pubTimestamp":1787738650,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals HY26 net loss narrows 22.5% to RMB 162.55 million; revenue rises to RMB 104.16 millionAlebund posted revenue of RMB 104.16 million, up 761.2%, driven by RMB 79.3 million AP306 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL7Q1XP2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662792769","title":"Alebund Pharmaceuticals (Jiangsu) Ltd - Board Did not Recommend Distribution of an Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2662792769","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662792769?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:01","pubTimestamp":1787738462,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0HX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662792744","title":"Alebund Pharmaceuticals (Jiangsu) Ltd - Hy Loss Attributable Rmb162.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662792744","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662792744?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:01","pubTimestamp":1787738462,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0HX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143863458","title":"Hong Kong Stock Alert | ALEBUND-B (09637) Surges Over 6% on Dual Catalysts of Index Inclusion and Earnings, with Mircera Commercialization Poised for Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1143863458","media":"Stock News","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143863458?lang=en_us&edition=fundamental","pubTime":"2026-08-25 15:00","pubTimestamp":1787641221,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) climbed more than 6% in early trading, last up 3.82% at HK$33.7, with turnover reaching HK$12.45 million.On the news front, Hang Seng Indexes Company recently announced the results...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","BK4588","BK1191","BK1161","09939","BK1574","159938","09637","BK1515","BK4585","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170273351","title":"Earning Preview: ALEBUND-B Q2 revenue expected to increase, institutions cautious on margin recovery","url":"https://stock-news.laohu8.com/highlight/detail?id=1170273351","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170273351?lang=en_us&edition=fundamental","pubTime":"2026-08-19 11:23","pubTimestamp":1787109824,"startTime":"0","endTime":"0","summary":"Abstract Alebund Pharmaceuticals-B will report its quarterly results on August 26, 2026 post-Market; this preview summarizes the latest quarter’s performance, current-quarter forecasts on revenue,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: ALEBUND-B Q2 revenue expected to increase, institutions cautious on margin recovery","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659148546","title":"Alebund Pharmaceuticals Held Extraordinary General Meeting; Auditor Appointment Approved","url":"https://stock-news.laohu8.com/highlight/detail?id=2659148546","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659148546?lang=en_us&edition=fundamental","pubTime":"2026-08-14 18:17","pubTimestamp":1786702628,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals held extraordinary general meeting; auditor appointment approvedAlebund Pharmaceuticals (Jiangsu) held an extraordinary general meeting on Aug. 14, 2026.Shareholders adopted a ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL3qLvt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162000898","title":"Alebund Pharmaceuticals Sets 26 August 2026 Board Meeting to Approve 1H26 Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1162000898","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162000898?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:43","pubTimestamp":1786621402,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals (Jiangsu) Limited announced that its board of directors will convene on Wednesday, 26 August 2026. The meeting’s agenda includes reviewing and approving the Group’s interim...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659712159","title":"Alebund Pharmaceuticals Schedules Board Meeting to Review Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659712159","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659712159?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:36","pubTimestamp":1786621010,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals schedules board meeting to review interim resultsAlebund Pharmaceuticals scheduled a board meeting for Aug. 26, 2026.Directors are set to review interim results for the six mon","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL8dQ2dZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657564891","title":"Alebund Pharma's Application for Hyperphosphatemia Drug Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2657564891","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657564891?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:33","pubTimestamp":1786102380,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals 's  new drug application for AP301 capsules was accepted for review by China's National Medical Products Administration.The drug has been developed for the treatment of hyperphosphatemia in patients with chronic kidney disease receiving maintenance dialysis.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172591515","title":"Alebund Pharma’s AP301 Capsule NDA Accepted by China’s NMPA for Dialysis-Related Hyperphosphatemia","url":"https://stock-news.laohu8.com/highlight/detail?id=1172591515","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172591515?lang=en_us&edition=fundamental","pubTime":"2026-08-07 18:05","pubTimestamp":1786097158,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals (Jiangsu) Limited announced that the National Medical Products Administration of China (NMPA) has accepted for review the New Drug Application (NDA) for AP301, a novel oral...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657461974","title":"Alebund Pharma Says China NMPA Accepts AP301 Hyperphosphatemia NDA for Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2657461974","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657461974?lang=en_us&edition=fundamental","pubTime":"2026-08-07 17:25","pubTimestamp":1786094750,"startTime":"0","endTime":"0","summary":"Alebund Pharma says China NMPA accepts AP301 hyperphosphatemia NDA for reviewNMPA accepted Alebund’s China NDA for AP301 capsules to treat hyperphosphatemia in chronic kidney disease patients on maintenance dialysis.Filing backed mainly by RESPOND-1, a China Phase III trial that met primary endpoints, showing non-inferiority to sevelamer carbonate at week 12.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alebund Pharmaceuticals  Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on August 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL1fB9sT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657619710","title":"Alebund Pharmaceuticals (Jiangsu) - Nmpa China Accepts Nda for AP301 Capsules for Hyperphosphatemia in Ckd Dialysis Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2657619710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657619710?lang=en_us&edition=fundamental","pubTime":"2026-08-07 17:25","pubTimestamp":1786094704,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nFWN4432DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657518686","title":"Alebund Pharma Expects H1 Revenue RMB 103 Million-RMB 106 Million, up About 750%-775%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657518686","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657518686?lang=en_us&edition=fundamental","pubTime":"2026-08-06 16:39","pubTimestamp":1786005588,"startTime":"0","endTime":"0","summary":"Alebund Pharma expects H1 revenue RMB 103 million-RMB 106 million, up about 750%-775%Alebund flagged revenue of RMB 103 million–RMB 106 million for the six months ended June 30, 2026, up about 750%–77","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL4z89TP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154239524","title":"Alebund Pharmaceuticals Completes 8.51 Million-Share Over-Allotment, Total Issued Capital Rises to 348.37 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1154239524","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154239524?lang=en_us&edition=fundamental","pubTime":"2026-08-05 16:52","pubTimestamp":1785919927,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals (Jiangsu) Limited issued and allotted 8.51 million H shares on 29 July 2026 following the full exercise of the over-allotment option disclosed on 24 July 2026. The shares were...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113931304","title":"Hong Kong Stock Moves: ALEBUND-B Rises Over 6% After Global Phase IIb Trial Milestone for AP306","url":"https://stock-news.laohu8.com/highlight/detail?id=1113931304","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113931304?lang=en_us&edition=fundamental","pubTime":"2026-08-03 15:44","pubTimestamp":1785743066,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) shares surged more than 6% in Hong Kong trading, reaching HK$29.06 by the time of writing, up 6.68%, with a turnover of HK$4.6856 million.According to a recent update from the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637","BK1515","IBBJ","159938","BMED","MDTX","BK1191","VXUS","BK4588","KCAI","BK1574","PSYK","IBBQ","BK4585","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197845152","title":"Alebund Pharmaceuticals Publishes July 2026 Articles of Association, Confirms RMB348.37 Million Capital and Governance Framework","url":"https://stock-news.laohu8.com/highlight/detail?id=1197845152","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197845152?lang=en_us&edition=fundamental","pubTime":"2026-07-29 21:24","pubTimestamp":1785331484,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals (Jiangsu) Limited, which is scheduled to list 56.76 million H shares on the Hong Kong Main Board on 29 June 2026 (CSRC filing date: 24 April 2026), released its updated...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655893917","title":"Alebund Pharmaceuticals Amends Bylaws to Update Registered Capital to RMB 348.37 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655893917","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655893917?lang=en_us&edition=fundamental","pubTime":"2026-07-29 21:04","pubTimestamp":1785330249,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals amends bylaws to update registered capital to RMB 348.37 millionAlebund Pharmaceuticals (Jiangsu) amended its articles to reflect a larger share capital following full exercise","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL6SD53t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141020089","title":"ALEBUND-B (09637) Issued 8.51 Million Shares Following Full Exercise of Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1141020089","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141020089?lang=en_us&edition=fundamental","pubTime":"2026-07-29 17:26","pubTimestamp":1785317175,"startTime":"0","endTime":"0","summary":"On July 29, 2026, ALEBUND-B (09637) issued a corporate announcement.According to the announcement, the company issued and allotted 8.5133 million H-shares on that date. This issuance was a direct...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637","BK1161","09939","BK1515","BK1191","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654955480","title":"Alebund Pharma Nets HK$185 Million From Full Exercise of IPO Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2654955480","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654955480?lang=en_us&edition=fundamental","pubTime":"2026-07-27 10:12","pubTimestamp":1785118356,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals   said the over-allotment option of its Hong Kong initial public offering was fully exercised on Friday, according to a same-day Hong Kong bourse filing.The biopharmaceutical company expects to raise about HK$184.7 million in additional net proceeds.The exercise involved the issue of 8.51 million additional H-shares at HK$22.60 each, representing about 15% of the total offer shares available under the global offering.Dealings in the over-allotment shares are expected to begin on July 29, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09637","FRHC","BK1191","KCE","REDS","BK4127","IPOS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":57,"code":"91000000","status":"200"}]}}